Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DA-5217
- Development stage
- Phase 1
- Lead developer
- Dong-A ST
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
DA-5217 is an investigational pharmaceutical compound currently in phase 1 clinical trials. Its primary development is for intravenous administration, with ongoing studies assessing the pharmacokinetics and safety of both diluted and undiluted formulations in healthy adults. The study is sponsored and developed by Dong-A ST, a South Korean pharmaceutical company. The specific mechanism of action and disease indication remain undisclosed at this stage of development. The drug is being administered as a single dose in a crossover study design, but no additional mechanistic, molecular, or class information has been publicly disclosed as of this time[1][2][3][4][5].
- Other names
- DA 5217DA5217DA-5217
Beyond the preview
Go deeper on DA-5217.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DA-5217.